{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:52:34Z","timestamp":1774468354109,"version":"3.50.1"},"reference-count":95,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.clinthera.2015.02.016","type":"journal-article","created":{"date-parts":[[2015,3,7]],"date-time":"2015-03-07T06:03:10Z","timestamp":1425708190000},"page":"1178-1194","source":"Crossref","is-referenced-by-count":45,"title":["Cardiometabolic Effects of a New Class of Antidiabetic Agents"],"prefix":"10.1016","volume":"37","author":[{"given":"Cyrus V.","family":"Desouza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anery","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.clinthera.2015.02.016_bib1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clinthera.2015.02.016_bib2","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","article-title":"Follow-up of blood-pressure lowering and glucose control in type 2 diabetes","volume":"371","author":"Zoungas","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clinthera.2015.02.016_bib3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1463-1326.2011.01380.x","article-title":"Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: Meta-analysis of randomized controlled trials","volume":"13","author":"Esposito","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.clinthera.2015.02.016_bib4","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1345\/aph.1R041","article-title":"Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: Meta-analysis","volume":"46","author":"Park","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.clinthera.2015.02.016_bib5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/dmrr.1184","article-title":"Predictors of response to dipeptidyl peptidase-4 inhibitors: Evidence from randomized clinical trials","volume":"27","author":"Monami","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"10.1016\/j.clinthera.2015.02.016_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/dmrr.2482","article-title":"Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials","volume":"30","author":"Zhang","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"10.1016\/j.clinthera.2015.02.016_bib7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/dmrr.1114","article-title":"Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus","volume":"26","author":"Scheen","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"10.1016\/j.clinthera.2015.02.016_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001844","article-title":"A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: An example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus","volume":"3","author":"Gross","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2015.02.016_bib9","first-page":"CD006739","article-title":"Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus","author":"Richter","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"10.1016\/j.clinthera.2015.02.016_bib10","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clinthera.2015.02.016_bib11","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.02.016_bib12","doi-asserted-by":"crossref","first-page":"e1369","DOI":"10.1136\/bmj.e1369","article-title":"Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-analysis","volume":"344","author":"Karagiannis","year":"2012","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.clinthera.2015.02.016_bib13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.amjcard.2012.04.061","article-title":"Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus","volume":"110","author":"Patil","year":"2012","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.clinthera.2015.02.016_bib14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.12000","article-title":"Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials","volume":"15","author":"Monami","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.clinthera.2015.02.016_bib15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/1755-5922.12075","article-title":"Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials with 55,141 participants","volume":"32","author":"Wu","year":"2014","journal-title":"Cardiovasc Ther"},{"issue":"7","key":"10.1016\/j.clinthera.2015.02.016_bib16","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/dom.12093","article-title":"Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus","volume":"15","author":"White","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.clinthera.2015.02.016_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11936-014-0353-y","article-title":"Dipeptidyl-peptidase-4 inhibitors and heart failure: Class effect, substance-specific effect, or chance effect?","volume":"16","author":"Standl","year":"2014","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"7","key":"10.1016\/j.clinthera.2015.02.016_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.numecd.2014.01.017","article-title":"Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials","volume":"24","author":"Monami","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"8","key":"10.1016\/j.clinthera.2015.02.016_bib19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.5694\/mja13.11279","article-title":"Dipeptidyl peptidase-4 inhibitors and cardiovascular safety","volume":"200","author":"Davis","year":"2014","journal-title":"Med J Aust"},{"issue":"5","key":"10.1016\/j.clinthera.2015.02.016_bib20","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/0091270008316885","article-title":"Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension","volume":"48","author":"Mistry","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2015.02.016_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-2840-11-3","article-title":"Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme","volume":"11","author":"Johansen","year":"2012","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.clinthera.2015.02.016_bib22","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/HYPERTENSIONAHA.110.156554","article-title":"Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans","volume":"56","author":"Marney","year":"2010","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.clinthera.2015.02.016_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2125.2011.03931.x","article-title":"The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses","volume":"72","author":"Ring","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.clinthera.2015.02.016_bib24","doi-asserted-by":"crossref","first-page":"e003277","DOI":"10.1161\/JAHA.112.003277","article-title":"Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients","volume":"2","author":"Ayaori","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.clinthera.2015.02.016_bib25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12933-014-0110-2","article-title":"DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study","volume":"13","author":"Nakamura","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.clinthera.2015.02.016_bib26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.02.016_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1475-2840-10-61","article-title":"Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: Focus on incretins","volume":"10","author":"Ansar","year":"2011","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.clinthera.2015.02.016_bib28","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1463-1326.2011.01362.x","article-title":"Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes","volume":"13","author":"Tremblay","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.clinthera.2015.02.016_bib29","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00125-006-0340-2","article-title":"Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes","volume":"49","author":"Matikainen","year":"2006","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.clinthera.2015.02.016_bib30","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00125-011-2447-3","article-title":"Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and\/or pioglitazone: A randomised double-blind placebo-controlled study","volume":"55","author":"Eliasson","year":"2012","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.clinthera.2015.02.016_bib31","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2337\/dc07-0627","article-title":"Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes","volume":"30","author":"Goldstein","year":"2007","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.clinthera.2015.02.016_bib32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1463-1326.2006.00704.x","volume":"9","author":"Nauck","year":"2007","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.clinthera.2015.02.016_bib33","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1463-1326.2009.01056.x","article-title":"Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial","volume":"11","author":"Jadzinsky","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.clinthera.2015.02.016_bib34","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2147\/VHRM.S3005","article-title":"Vildagliptin: A new oral treatment for type 2 diabetes mellitus","volume":"4","author":"Mathieu","year":"2008","journal-title":"Vasc Health Risk Manag"},{"issue":"1","key":"10.1016\/j.clinthera.2015.02.016_bib35","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.4158\/EP11264.CR","article-title":"Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide","volume":"18","author":"Iyer","year":"2012","journal-title":"Endocr Pract"},{"issue":"9","key":"10.1016\/j.clinthera.2015.02.016_bib36","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic safety of incretin-based drugs--FDA and EMA assessment","volume":"370","author":"Egan","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clinthera.2015.02.016_bib37","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.clinthera.2015.02.016_bib38","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.clinthera.2015.02.016_bib39","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dc06-2375","article-title":"Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes","volume":"30","author":"Kim","year":"2007","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.clinthera.2015.02.016_bib40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1463-1326.2011.01493.x","article-title":"Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme","volume":"14","author":"Zinman","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.clinthera.2015.02.016_bib41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.clinthera.2015.02.016_bib42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3810\/pgm.2014.10.2821","article-title":"Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes","volume":"126","author":"Kuritzky","year":"2014","journal-title":"Postgrad Med"},{"issue":"11","key":"10.1016\/j.clinthera.2015.02.016_bib43","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1177\/1060028014545807","article-title":"Albiglutide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes","volume":"48","author":"Trujillo","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.clinthera.2015.02.016_bib44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S2213-8587(13)70214-6","article-title":"Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): A randomised, open-label, multicentre, non-inferiority phase 3 study","volume":"2","author":"Pratley","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2015.02.016_bib45","first-page":"25","article-title":"Lixisenatide as add-on therapy to basal insulin","volume":"8","author":"Brown","year":"2013","journal-title":"Drug Des Devel Ther"},{"issue":"7-8","key":"10.1016\/j.clinthera.2015.02.016_bib46","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1345\/aph.1Q024","article-title":"Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"45","author":"Pinelli","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"9662","key":"10.1016\/j.clinthera.2015.02.016_bib47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"issue":"1\u20133","key":"10.1016\/j.clinthera.2015.02.016_bib48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.regpep.2008.07.003","article-title":"Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes","volume":"151","author":"Linnebjerg","year":"2008","journal-title":"Regul Pept"},{"issue":"4","key":"10.1016\/j.clinthera.2015.02.016_bib49","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"issue":"9739","key":"10.1016\/j.clinthera.2015.02.016_bib50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.clinthera.2015.02.016_bib51","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","article-title":"DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes","volume":"96","author":"Blevins","year":"2011","journal-title":"J Clin Endocrinol Meta"},{"issue":"9683","key":"10.1016\/j.clinthera.2015.02.016_bib52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clinthera.2015.02.016_bib53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2011-2407","article-title":"Glucagon like peptide-1 receptor expression in the human thyroid gland","volume":"97","author":"Gier","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.clinthera.2015.02.016_bib54","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.clinthera.2015.02.016_bib55","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.diabres.2014.01.010","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials","volume":"103","author":"Monami","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2015.02.016_bib56","doi-asserted-by":"crossref","first-page":"g2366","DOI":"10.1136\/bmj.g2366","article-title":"Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: Systematic review and meta-analysis of randomised and non-randomised studies","volume":"348","author":"Li","year":"2014","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clinthera.2015.02.016_bib57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.112.091215","article-title":"A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity","volume":"127","author":"Noyan-Ashraf","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.clinthera.2015.02.016_bib58","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1161\/CIRCINTERVENTIONS.112.968388","article-title":"Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia","volume":"5","author":"Lonborg","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.clinthera.2015.02.016_bib59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1475-2840-10-22","article-title":"Cardiovascular safety of exenatide BID: An integrated analysis from controlled clinical trials in participants with type 2 diabetes","volume":"10","author":"Ratner","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2015.02.016_bib60","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2840-9-6","article-title":"Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: A double-blind, placebo-controlled, randomized pilot study","volume":"9","author":"Gill","year":"2010","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"10.1016\/j.clinthera.2015.02.016_bib61","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/dom.12085","article-title":"Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: A meta-analysis of clinical trials","volume":"15","author":"Wang","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.clinthera.2015.02.016_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001986","article-title":"Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis","volume":"3","author":"Robinson","year":"2013","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.clinthera.2015.02.016_bib63","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1479164112449562","article-title":"Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research","volume":"10","author":"Irace","year":"2013","journal-title":"Diab Vasc Dis Res"},{"issue":"1","key":"10.1016\/j.clinthera.2015.02.016_bib64","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1475-2840-13-49","article-title":"Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study","volume":"13","author":"Rizzo","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2015.02.016_bib65","first-page":"621","article-title":"Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers","volume":"8","author":"Chiquette","year":"2012","journal-title":"Vasc Health Risk Manag"},{"issue":"6","key":"10.1016\/j.clinthera.2015.02.016_bib66","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2337\/dc09-1914","article-title":"DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks","volume":"33","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.clinthera.2015.02.016_bib67","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1463-1326.2010.01330.x","article-title":"Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes","volume":"13","author":"Davies","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.clinthera.2015.02.016_bib68","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2337\/dc12-2709","article-title":"Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.clinthera.2015.02.016_bib69","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2337\/dc14-0024","article-title":"HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin","volume":"37","author":"Ahren","year":"2014","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.clinthera.2015.02.016_bib70","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s00125-014-3360-3","article-title":"HARMONY 4: Randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea","volume":"57","author":"Weissman","year":"2014","journal-title":"Diabetologia"},{"issue":"9701","key":"10.1016\/j.clinthera.2015.02.016_bib71","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.clinthera.2015.02.016_bib72","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4066\/AMJ.2014.2181","article-title":"SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes","volume":"7","author":"Moses","year":"2014","journal-title":"Australas Med J"},{"issue":"4","key":"10.1016\/j.clinthera.2015.02.016_bib73","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"issue":"9733","key":"10.1016\/j.clinthera.2015.02.016_bib74","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clinthera.2015.02.016_bib75","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2015.02.016_bib76","article-title":"Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +\/\u2212 oral agents in type 2 diabetes","author":"Matthews","year":"2012","journal-title":"European Association of Diabetes (EASD)"},{"key":"10.1016\/j.clinthera.2015.02.016_bib77","first-page":"1","article-title":"Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting","author":"Buysman","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.clinthera.2015.02.016_bib78","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"Haring","year":"2014","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.clinthera.2015.02.016_bib79","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Haring","year":"2013","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.clinthera.2015.02.016_bib80","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1463-1326.2012.01659.x","article-title":"Dapagliflozin monotherapy in drug-naive patients with diabetes: A randomized-controlled trial of low-dose range","volume":"14","author":"Bailey","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.clinthera.2015.02.016_bib81","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jdiacomp.2013.05.004","article-title":"Urinary tract infections in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J Diabetes Complications"},{"issue":"3","key":"10.1016\/j.clinthera.2015.02.016_bib82","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3810\/pgm.2013.05.2650","article-title":"Genital mycotic infections in patients with diabetes","volume":"125","author":"Nyirjesy","year":"2013","journal-title":"Postgrad Med"},{"issue":"10","key":"10.1016\/j.clinthera.2015.02.016_bib83","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40264-014-0213-4","article-title":"Safety profile of dapagliflozin for type 2 diabetes: Pooled analysis of clinical studies for overall safety and rare events","volume":"37","author":"Ptaszynska","year":"2014","journal-title":"Drug Saf"},{"issue":"11","key":"10.1016\/j.clinthera.2015.02.016_bib84","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1517\/14740338.2014.959488","article-title":"A safety evaluation of canagliflozin: A first-in-class treatment for type 2 diabetes","volume":"13","author":"Boyle","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.clinthera.2015.02.016_bib85","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/2042018814553965","article-title":"Sodium glucose transporter protein 2 inhibitors: Focusing on the kidney to treat type 2 diabetes","volume":"5","author":"Peene","year":"2014","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.clinthera.2015.02.016_bib86","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/jch.12425","article-title":"Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus","volume":"16","author":"Weir","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2015.02.016_bib87","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","author":"Tikkanen","year":"2014","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.clinthera.2015.02.016_bib88","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.clinthera.2015.02.016_bib89","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/dom.12187","article-title":"Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years","volume":"16","author":"Wilding","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.02.016_bib90","first-page":"37","article-title":"Empagliflozin as add on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM)","author":"Rosenstock","year":"2013","journal-title":"Can J Diabetes"},{"issue":"9896","key":"10.1016\/j.clinthera.2015.02.016_bib91","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.02.016_bib92","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.clinthera.2015.02.016_bib93","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/dom.12261","article-title":"Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes","volume":"16","author":"Dziuba","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2015.02.016_bib94","first-page":"S14","article-title":"Standards of medical care in diabetes--2014","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.clinthera.2015.02.016_bib95","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.2337\/dc13-0356","article-title":"Rationale and design of the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE)","volume":"36","author":"Nathan","year":"2013","journal-title":"Diabetes Care"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815000867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815000867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T15:58:00Z","timestamp":1537804680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815000867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":95,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0149291815000867"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.02.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}